专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

KR20180056777A B형 간염 바이러스를 강력하게 중화하는 항체 및 그의 용도 审中-公开
公开(公告)号：KR20180056777A
公开(公告)日：2018-05-29
申请号：KR20187012979
申请日：2016-10-07
申请人： HUMABS BIOMED SA
发明人： CORTI DAVIDE
IPC分类号： C07K16/08 , A61K39/00 , A61K39/42 , C07K16/10
CPC分类号： C07K16/10 , A61K39/42 , A61K2039/505 , C07K16/082 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C12N2730/10111
摘要： 본발명은, B형간염표면항원 (HBsAg)의항원성루프영역에결합하고 B형간염바이러스 (HBV) 및델타간염바이러스 (HDV) 감염모두를강력하게중화시키는항체, 및그의항원결합단편에관한것이다. 본발명은또한항체및 항원결합단편이결합하는에피토프는물론, 그러한항체및 항체단편을암호화하는핵산및 생산하는세포에관한것이다. 더불어, 본발명은 B형간염및 D형간염의진단, 방지및 치료에서의본 발명의항체및 항체단편의용도에관한것이다.

2. 发明公开

KR1020100109556A 말라리아 백신 无效
标题翻译：疟疾疫苗
公开(公告)号：KR1020100109556A
公开(公告)日：2010-10-08
申请号：KR1020107016404
申请日：2008-12-18
申请人： 글락소스미스클라인 바이오로지칼즈 에스.에이.
发明人： 레모이네,도미니크,잉그리드 , 워터스,플로렌스,에밀리,쟌느,프랑소와즈
IPC分类号： A61K39/015 , A61K39/39 , A61K47/18 , A61P31/00
CPC分类号： A61K39/015 , A61K9/19 , A61K2039/55555 , A61K2039/55566 , A61K2039/55572 , A61K2039/55577 , A61K2039/6075 , C12N2730/10111 , Y02A50/412
摘要： 본 발명은 하기를 포함하는 말라리아 백신용 성분에 관한 것이다: a) 면역원성 입자 RTS,S 및/또는 b) 1개 이상의 삼일열원충(
P.
vivax ) 균주의 CS 단백질에서 유래된 면역원성 입자 및 B형 간염균(
Hepatitis
B )으로부터의 S 항원 및 임의로 비융합된 S 항원, 또는 c) RTS, CSV-S 및 임의로 비융합된 S 항원을 포함하는 면역원성 입자 및 d) 1개 이상의 티올 작용기를 지닌 안정화제 또는 이들의 혼합물을 포함하는 안정화제. 또한 본 발명은 상기 성분의 제조 방법, 이의 의약으로서의 용도(특히 말라리아 감염의 예방에서), 상기 성분을 포함하는 조성물/백신 및 백신의 용도(특히 치료적 용도)를 개시한다.

3. 发明公开

KR1020090052521A 세포 영상 기법을 이용한 ＨＢＶ 캡시드 단백질과 표면단백질 간 상호작용 측정 방법과 이를 이용한 ＨＢＶ 증식억제물질의 검색방법 失效
标题翻译：使用细胞成像检测HBV CAPSID和表面蛋白的相互作用方法，以及使用其进行HBV增殖的抑制剂筛选方法
公开(公告)号：KR1020090052521A
公开(公告)日：2009-05-26
申请号：KR1020070119060
申请日：2007-11-21
申请人： 한국과학기술연구원
发明人： 전혜성 , 오수진 , 유연규 , 김윤경
IPC分类号： G01N33/533 , G01N33/53 , G01N33/68 , C12N15/00
CPC分类号： G01N33/5035 , C07K2319/60 , C07K2319/735 , G01N33/582 , G01N2333/02 , C07K14/005 , C07K2319/00 , C12N15/85 , C12N2730/10111 , G01N33/6845 , G01N2500/00
摘要： The present invention relates to a method for screening an inhibitory agent of HBV proliferation by measuring the interaction (binding strength) between capsid protein and surface protein, necessary for the proliferation of HBV, by using cellular imaging, more precisely a method for measuring changes on cellular imaging caused by the interaction between a fusion protein containing PreS domain of HBV surface protein and PH (Pleckstrin homology) domain sequence and a fusion protein containing capsid protein and fluorescence protein (GFP) interacting with the said fusion protein. The method of the present invention detecting the interaction between proteins necessary for HBV proliferation at cellular level can be effectively used for the screening of a novel inhibitory agent of HBV proliferation at cellular level.

4. 发明公开

KR1020170118706A B형 간염 감염을 치료하는 유도체 및 그 방법 审中-实审
标题翻译：衍生物和治疗乙型肝炎感染的方法
公开(公告)号：KR1020170118706A
公开(公告)日：2017-10-25
申请号：KR1020177020897
申请日：2015-12-30
申请人： 노비라 테라퓨틱스, 인코포레이티드
发明人： 하트먼조지디. , 쿠덕스콧
IPC分类号： C07D471/04 , A61K31/437 , A61K31/501 , A61K31/5377 , A61K38/21 , A61K39/29 , A61K45/06 , C12N7/00
CPC分类号： C07D471/04 , A61K31/437 , A61K31/4545 , A61K31/501 , A61K31/5377 , A61K38/212 , A61K39/292 , A61K45/06 , A61P31/12 , C12N7/00 , C12N2730/10111 , C12N2730/10134 , C12N2730/10171 , A61K2300/00
摘要： HBV 감염치료를필요로하는대상에서 HBV 감염치료에유용한화합물, 이들의약제학적조성물, 및상기대상에서 HBV 감염을억제하거나, 방지하거나, 예방하는방법이본 명세서에제공된다.
摘要翻译：本文提供了在需要治疗HBV感染的受试者中治疗HBV感染的化合物，其药物组合物以及在所述受试者中抑制，预防或预防HBV感染的方法。

5. 发明公开

KR1020080043775A 표적 치료용 회피 돌연변이체에 대한 면역 반응의 유발방법 및 조성물 无效
标题翻译：针对特定治疗方法免疫应答的组合物和方法
公开(公告)号：KR1020080043775A
公开(公告)日：2008-05-19
申请号：KR1020087003088
申请日：2006-07-10
申请人： 글로브이뮨
发明人： 아펠리언,데이비드 , 프란주소프,알렉스 , 로델,티모시,씨.
IPC分类号： C12N15/81
CPC分类号： A61K47/48776 , A61K31/506 , A61K39/0011 , A61K39/02 , A61K39/12 , A61K39/21 , A61K39/29 , A61K39/292 , A61K2039/5154 , A61K2039/523 , C12N15/81 , C12N2730/10111 , C12N2730/10134 , C12N2740/16211 , C12N2740/16234 , C12N2770/24211 , C12N2770/24234
摘要： Provided herein are cells, vectors and viruses in association with a mutant polypeptide that has emerged in response to a therapeutic or prophylactic agent; compositions comprising such cells, vectors and viruses and methods for their use in eliciting an immune response to the mutant polypeptide. In some examples, the immune response is a cellular immune response.
摘要翻译：本文提供的是与响应于治疗或预防剂而出现的突变多肽相关联的细胞，载体和病毒; 包含这样的细胞，载体和病毒的组合物和用于引发对突变多肽的免疫应答的方法。在一些实例中，免疫应答是细胞免疫应答。

6. 发明公开

KR1020160061304A 표적 지향성 펩타이드를 포함하는 재조합 자기조립성 단백질 및 그의 용도 审中-实审
标题翻译：包含目标特异性肽的重组蛋白自组装蛋白及其用途
公开(公告)号：KR1020160061304A
公开(公告)日：2016-05-31
申请号：KR1020160061899
申请日：2016-05-20
申请人： 고려대학교 산학협력단
发明人： 이지원 , 권구철
IPC分类号： C07K19/00 , C07K14/005 , C07K14/47 , C07K14/71 , C07K14/78 , C12N15/09 , A61K47/48 , B82B1/00 , B82Y5/00
CPC分类号： A61N5/062 , A61K49/0428 , C07K14/005 , C07K14/71 , C07K2319/20 , C07K2319/21 , C07K2319/32 , C12N2730/10122 , C12N2730/10123 , C12N2730/10133 , C12N2810/855 , C07K19/00 , A61K47/66 , B82B1/00 , B82Y5/00 , C07K14/47 , C07K14/78 , C07K2319/00 , C12N15/09 , C12N2730/10111
摘要： 본발명은표적지향성펩타이드를포함하는재조합자기조립성단백질및 그의용도에관한것이다. 본발명에따른표적지향성펩타이드를포함하는재조합자기조립성단백질은추가적인표적지향성부여과정을필요로하지않기때문에화학적결합제또는안정화제등의보조제를사용하지않고도원하는약물을표적조직또는표적세포로전달하는것이가능하며, 이로써광열치료, 약물전달또는이미징등에사용가능하다. 특히, 본발명에따르면추가적인표면안정화과정이나표적지향성부여과정없이도, 표적지향성을가지면서균일한고밀도의금 나노입자가단백질표면에결합되어있는금-단백질나노입자융합체를제작할수 있다. 본발명에따른금-단백질나노입자융합체는기존의금 나노입자에비하여 pH의변화및 농도의변화에구조적안정성을보이며표적지향성또한우수하므로, 금나노입자의광열치료요법에있어서획기적인활용도의증진을가져다줄 수있다.
摘要翻译：本发明涉及包含目标指导肽的重组自组装蛋白及其用途。包含根据本发明的靶向指导肽的重组自组装蛋白不需要另外赋予靶指向性的步骤，因此可以将所需药物递送至靶组织或靶细胞而不使用辅助剂如化学品偶联剂或稳定剂。因此，包含靶向指导肽的重组自组装蛋白质可用于光热处理，药物递送或成像。特别地，根据本发明，可以制造金属 - 蛋白质纳米颗粒熔融体，其中具有目标方向性和均匀高密度的金纳米颗粒与蛋白质的表面偶联，而无需附加的表面稳定化步骤或靶向性赋予步骤。与常规金纳米粒子相比，本发明的金属蛋白质纳米颗粒熔融体相对于pH变化和浓度变化而言具有结构稳定性，并且还具有优异的目标方向性。因此，可以显着提高光热处理中金属纳米粒子的利用。

7. 发明公开

KR1020150130284A 암 백신 및 이를 이용한 치료 방법 审中-实审
标题翻译：癌症疫苗及其治疗方法
公开(公告)号：KR1020150130284A
公开(公告)日：2015-11-23
申请号：KR1020157024377
申请日：2014-03-14
申请人： 더 트러스티스 오브 더 유니버시티 오브 펜실바니아
发明人： 웨이너,데이비드 , 무투마니,카루피아 , 월터스,즈웰 , 얀,지안
IPC分类号： A61K39/00 , A61K48/00 , C07K14/47 , C07K14/60 , C12N9/02 , C12N9/12 , C12N15/63
CPC分类号： A61K39/0011 , A61K39/3955 , A61K2039/505 , A61K2039/53 , A61K2039/54 , A61K2039/55522 , A61K2039/55527 , A61K2039/575 , C12N9/0071 , C12N2710/20034 , C12N2730/10111 , C12N2770/24234 , C12Y114/18001
摘要： 암치료를위한조성물및 방법, 특히, 종양성장을치료하고이에대하여보호를제공하는백신이본원에개시된다.

8. 发明公开

KR1020000029747A 말라리아에대한백신조성물 无效
标题翻译：疫苗组合物疟疾
公开(公告)号：KR1020000029747A
公开(公告)日：2000-05-25
申请号：KR1019997000855
申请日：1997-07-31
申请人： 글락소스미스클라인 바이오로지칼즈 에스.에이.
发明人： 코헨,조셉
IPC分类号： A61K39/015
CPC分类号： A61K39/015 , A61K39/39 , A61K2039/55566 , A61K2039/55572 , A61K2039/55577 , A61K2039/575 , C12N2730/10111 , Y02A50/412
摘要： PURPOSE: Provided are a novel vaccine composition and to its use in medicine, particularly in the prevention of malaria infections. The vaccine composition useful in the prevention or treatment of malaria comprises a plurality of malaria-derived antigens in combination with an adjuvant which is a preferential stimulator of TH1 cell response. CONSTITUTION: A vaccine composition for use in the prevention or treatment of malaria, comprising a plurality of malaria-derived antigens in combination with an adjuvant comprising MPL QS21 and an oil-in-water emulsion which is a preferential stimulator of TH1 cell response. The malaria antigens are selected from the group consisting of: a hybrid protein comprising substantially all the C-terminal portion of the CS protein, four or more tandem repeats of the immunodominant region, and the surface antigen from Hepatitis B virus (HBsAg); the TRAP of a cloned isolate of P. falciparum from Thailand known as T/9/96, and proteins having at least 80% homology thereto, and immunogenic derivatives including g fragments thereof; the 16kD protein described in International Patent Application No.WO 91/18922, and proteins having at least 80% homology thereto, and immunogenic derivatives including g fragments thereof; the apical membrane antigen (AMA-1) of P. falciparum or P. vivax, and proteins having at least 80% homology thereto, and immunogenic derivatives including g fragments thereof; the circumpolar protein (cs) of P. falciparum or P. vivax, and proteins having at least 80% homology thereto, and immunogenic derivatives including g fragments thereof; the MSP-1 of P. falciparum or P. vivax (US Patent No 4,837,016), and proteins having at least 80% homology thereto, and immunogenic derivatives including fragments thereof; other exoerythrocytic stage proteins and immunogenic derivatives including g fragments thereof; and optionally, blood stage proteins and immunogenic derivatives including g fragments thereof; The method of treating or preventing malaria, which comprises administering to a patient in need thereof an effective amount of a vaccine composition.
摘要翻译：目的：提供一种新型疫苗组合物及其在医药中的应用，特别是预防疟疾感染。可用于预防或治疗疟疾的疫苗组合物包含多种疟疾来源的抗原，其与作为TH1细胞应答的优选刺激剂的佐剂组合。构成：用于预防或治疗疟疾的疫苗组合物，其包含多种疟疾来源的抗原与包含MPL QS21的佐剂和作为TH1细胞应答的优选刺激剂的水包油乳剂。疟疾抗原选自：包含CS蛋白的基本上所有C-末端部分的杂交蛋白，免疫显性区域的四个或更多个串联重复序列和来自乙型肝炎病毒（HBsAg）的表面抗原; 来自泰国称为T / 9/96的来自泰国的恶性疟原虫的克隆分离物的TRAP和与其具有至少80％同源性的蛋白质，以及包含其g片段的免疫原性衍生物; 国际专利申请WO 91/18922中所述的16kD蛋白质和与其具有至少80％同源性的蛋白质，以及包含其g片段的免疫原性衍生物; 恶性疟原虫或间日疟原虫的顶端膜抗原（AMA-1）和与其具有至少80％同源性的蛋白质，以及包含其g片段的免疫原性衍生物; 恶性疟原虫或间日疟原虫的环状蛋白（cs）和与其同源性至少为80％的蛋白质，以及包含其g片段的免疫原性衍生物; 恶性疟原虫或间日疟原虫的MSP-1（美国专利号4,837,016）和与其具有至少80％同源性的蛋白质和包括其片段的免疫原性衍生物; 其他外源性红细胞期蛋白和包括其g片段的免疫原性衍生物; 和任选的血液阶段蛋白质和包括其g片段的免疫原性衍生物; 治疗或预防疟疾的方法，其包括向有需要的患者施用有效量的疫苗组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式